Drug Profile
BB 3241
Latest Information Update: 03 Jun 1997
Price :
$50
*
At a glance
- Originator British Biotech
- Class Antirheumatics
- Mechanism of Action Metalloprotease inhibitors; Peptide hydrolase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Rheumatoid arthritis
Most Recent Events
- 03 Jun 1997 Discontinued-Preclinical for Rheumatoid arthritis in United Kingdom (PO)
- 29 Aug 1996 New profile
- 29 Aug 1996 Preclinical development for Rheumatoid arthritis in United Kingdom (PO)